Standout Papers

The safety and immunogenicity of two Zika virus mRNA vaccine candidates in healthy flavivirus baseline seropositive and seronegative adu... 2023 2026 202483
  1. The safety and immunogenicity of two Zika virus mRNA vaccine candidates in healthy flavivirus baseline seropositive and seronegative adults: the results of two randomised, placebo-controlled, dose-ranging, phase 1 clinical trials (2023)
    Brandon Essink, Laurence Chu et al. The Lancet Infectious Diseases

Immediate Impact

2 by Nobel laureates 1 from Science/Nature 51 standout
Sub-graph 1 of 24

Citing Papers

Global trends in antibiotic consumption during 2016–2023 and future projections through 2030
2024 Standout
mRNA vaccines for infectious diseases — advances, challenges and opportunities
2024 Standout
6 intermediate papers

Works of Laurence Chu being referenced

The safety and immunogenicity of two Zika virus mRNA vaccine candidates in healthy flavivirus baseline seropositive and seronegative adults: the results of two randomised, placebo-controlled, dose-ranging, phase 1 clinical trials
2023 Standout
Safety and Immunogenicity of an mRNA-Based Human Metapneumovirus and Parainfluenza Virus Type 3 Combined Vaccine in Healthy Adults
2022
and 4 more

Author Peers

Author Last Decade Papers Cites
Laurence Chu 241 367 51 133 22 612
Angela Carville 300 308 21 75 28 674
Marzia Facchini 461 247 39 85 29 679
Jing-Hui Tian 165 435 12 162 14 669
Alexandre Gaymard 268 479 18 158 29 719
Jayanthi Wolf 117 274 12 195 25 561
Clinton R. Paden 243 353 22 65 22 613
Steve Black 304 209 94 80 26 717
Massimiliano Secchi 185 363 12 113 20 675
Obeid E. Obeid 268 144 36 167 26 542
Janice Lo 533 219 128 131 26 718

All Works

Loading papers...

Rankless by CCL
2026